$CELU
Celularity Inc Stock $celu

$celu Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023023462 Filed on May 22, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$2.938M	$3.935M	$5.935M
YoY Change	-22.19%	-33.7%	123.12%
Cost Of Revenue	$800.0K	$2.003M	$4.026M
YoY Change	-74.83%	-50.25%
Gross Profit	$2.136M	$1.932M	$1.909M
YoY Change	257.79%	1.2%	34.63%
Gross Profit Margin	72.7%	49.1%	32.17%
Selling, General & Admin	$12.83M	$13.93M	$16.46M
YoY Change	-17.64%	-15.35%	115.84%
% of Gross Profit	600.47%	721.22%	862.23%
Research & Development	$8.604M	$16.95M	$21.67M
YoY Change	-66.06%	-21.79%	27.56%
% of Gross Profit	402.81%	877.38%	1135.31%
Depreciation & Amortization	$2.330M	$2.363M	$2.284M
YoY Change	0.47%	3.46%	17.98%
% of Gross Profit	109.08%	122.31%	119.64%
Operating Expenses	$21.43M	$30.89M	$38.13M
YoY Change	-698.94%	-19.01%	54.91%
Operating Profit	-$42.48M	-$63.87M	-$41.61M
YoY Change	-1117.39%	53.48%	-6.26%
Interest Expense	-$1.040M	-$161.0K	$6.000K
YoY Change	-2636.59%	-2783.33%	-78.48%
% of Operating Profit
Other Income/Expense, Net	-$5.473M	-$147.0K	-$21.25M
YoY Change	-112.54%	-99.31%	-42.78%
Pretax Income	-$47.95M	-$64.02M	-$62.87M
YoY Change	-200.22%	1.83%	-22.9%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$47.95M	-$64.02M	-$62.87M
YoY Change	-200.26%	1.83%	-22.9%
Net Earnings / Revenue	-1632.03%	-1626.86%	-1059.26%
Basic Earnings Per Share	-$0.27	-$0.41	-$0.48
Diluted Earnings Per Share	-$0.27	-$0.41	-$482.1K
COMMON SHARES
Basic Shares Outstanding	180.5M	165.0M	130.4M
Diluted Shares Outstanding	176.6M	155.4M	130.4M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.100M	$8.532M	$48.04M
YoY Change	-91.84%	-82.24%	167575.39%
Cash & Equivalents	$3.084M	$8.532M	$62.86M
Short-Term Investments
Other Short-Term Assets	$4.300M	$5.823M	$6.971M
YoY Change	-30.21%	-16.47%	11428.03%
Inventory	$5.738M	$5.484M	$14.72M
Prepaid Expenses
Receivables	$4.900M	$5.165M	$6.014M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$18.04M	$25.00M	$75.74M
YoY Change	-76.1%	-66.99%	76019.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$72.62M	$74.06M	$77.96M
YoY Change	-19.81%	-5.01%
Goodwill	$90.06M	$90.06M	$123.3M
YoY Change		-26.96%
Intangibles	$12.11M	$120.5M	$122.6M
YoY Change		-1.79%
Long-Term Investments
YoY Change
Other Assets	$326.0K	$352.0K	$18.86M
YoY Change	-98.18%	-98.13%	43658.7%
Total Long-Term Assets	$228.4M	$337.4M	$358.5M
YoY Change	-35.46%	-5.87%	22.83%
TOTAL ASSETS
Total Short-Term Assets	$18.04M	$25.00M	$75.74M
Total Long-Term Assets	$228.4M	$337.4M	$358.5M
Total Assets	$246.4M	$362.4M	$434.2M
YoY Change	-42.6%	-16.53%	48.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.45M	$8.755M	$10.42M
YoY Change	21.73%	-15.96%	106.7%
Accrued Expenses	$33.40M	$24.56M	$13.44M
YoY Change	63.07%	82.76%
Deferred Revenue	$2.311M	$2.199M
YoY Change
Short-Term Debt	$16.82M	$30.95M	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$64.98M	$66.46M	$26.03M
YoY Change	97.26%	155.27%	404.52%
LONG-TERM LIABILITIES
Long-Term Debt	$17.00M	$4.745M	$0.00
YoY Change
Other Long-Term Liabilities	$315.0K	$318.0K	$318.3M
YoY Change	-99.87%	-99.9%	819.67%
Total Long-Term Liabilities	$315.0K	$318.0K	$318.3M
YoY Change	-99.87%	-99.9%	819.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.98M	$66.46M	$26.03M
Total Long-Term Liabilities	$315.0K	$318.0K	$318.3M
Total Liabilities	$127.9M	$206.8M	$344.3M
YoY Change	-54.18%	-39.94%	765.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$757.5M	-$709.5M	-$722.6M
YoY Change		-1.8%
Common Stock	$18.00K	$17.00K	$14.00K
YoY Change		21.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$118.5M	$155.6M	$89.91M
YoY Change
Total Liabilities & Shareholders Equity	$246.4M	$362.4M	$434.2M
YoY Change	-42.6%	-16.53%	48.74%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$47.95M	-$64.02M	-$62.87M
YoY Change	-200.26%	1.83%	-22.9%
Depreciation, Depletion And Amortization	$2.330M	$2.363M	$2.284M
YoY Change	0.47%	3.46%	17.98%
Cash From Operating Activities	-$11.02M	-$15.00M	-$34.25M
YoY Change	-69.66%	-56.22%	36.57%
INVESTING ACTIVITIES
Capital Expenditures	$30.00K	$209.0K	$1.454M
YoY Change	-102.08%	-85.63%	-1.69%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$30.00K	-$3.209M	-$1.454M
YoY Change	-97.92%	120.7%	-1.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.610M	12.76M	46.50M
YoY Change	-79.76%	-72.56%	-1060.24%
NET CHANGE
Cash From Operating Activities	-11.02M	-15.00M	-34.25M
Cash From Investing Activities	-30.00K	-3.209M	-1.454M
Cash From Financing Activities	5.610M	12.76M	46.50M
Net Change In Cash	-5.440M	-5.445M	10.79M
YoY Change	-45.81%	-150.47%	-134.36%
FREE CASH FLOW
Cash From Operating Activities	-$11.02M	-$15.00M	-$34.25M
Capital Expenditures	$30.00K	$209.0K	$1.454M
Free Cash Flow	-$11.05M	-$15.20M	-$35.71M
YoY Change	-68.32%	-57.42%	34.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001752828
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q1	celu	Software Cease Use Costs SoftwareCeaseUseCosts
CY2023Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.0033
CY2023Q1	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38914
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Celularity Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1702591
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	170 Park Ave
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Florham Park
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07932
CY2023Q1	dei	City Area Code CityAreaCode	(908)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	768-2170
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	180530272
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8532000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13966000
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2350000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1789000
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3050000
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	4452000
CY2023Q1	celu	Promissory Notes Receivable PromissoryNotesReceivable	2115000
CY2022Q4	celu	Promissory Notes Receivable PromissoryNotesReceivable	2514000
CY2023Q1	us-gaap	Inventory Net InventoryNet	5484000
CY2022Q4	us-gaap	Inventory Net InventoryNet	5308000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5823000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7262000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	25004000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	33502000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74056000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75655000
CY2023Q1	us-gaap	Goodwill Goodwill	90061000
CY2022Q4	us-gaap	Goodwill Goodwill	119694000
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120453000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120994000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13079000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13060000
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14825000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14836000
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	24586000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	22949000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	352000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	376000
CY2023Q1	us-gaap	Assets Assets	362416000
CY2022Q4	us-gaap	Assets Assets	401066000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8755000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5810000
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9559000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9069000
CY2023Q1	celu	Accrued Research And Development Software AccruedResearchAndDevelopmentSoftware	15000000
CY2022Q4	celu	Accrued Research And Development Software AccruedResearchAndDevelopmentSoftware	7333000
CY2023Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	30945000
CY2023Q1	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	32382000
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	30945000
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	37603000
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2199000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2273000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	66458000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62088000
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2325000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2219000
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	87013000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	105945000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28049000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27985000
CY2023Q1	celu	Noncurrent Research And Development Software NoncurrentResearchAndDevelopmentSoftware	16008000
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	4745000
CY2023Q1	celu	Warrant Liability WarrantLiability	1863000
CY2022Q4	celu	Warrant Liability WarrantLiability	3598000
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	9000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	9000
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	318000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	321000
CY2023Q1	us-gaap	Liabilities Liabilities	206788000
CY2022Q4	us-gaap	Liabilities Liabilities	202165000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165030414
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165030414
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148921187
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148921187
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	17000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	862457000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	844373000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2667000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-709513000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-645496000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	155628000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	198901000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	362416000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	401066000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3935000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5935000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16951000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21673000
CY2023Q1	celu	Software Cease Use Costs SoftwareCeaseUseCosts	23675000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13934000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16460000
CY2023Q1	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-18932000
CY2022Q1	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	4849000
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29633000
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	541000
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	541000
CY2023Q1	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	67805000
CY2022Q1	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	47549000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-63870000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-41614000
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	116000
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	6000
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	277000
CY2022Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1735000
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	20932000
CY2023Q1	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	1280000
CY2022Q1	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	0
CY2023Q1	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-441000
CY2022Q1	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-327000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-147000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21253000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64017000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-62867000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-64017000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62867000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	2658000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	0
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2658000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61359000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62867000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155365048
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155365048
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130398811
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	130398811
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	198901000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	300000
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3358000
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	53000
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	136000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	274000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3988000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent	2810000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-64017000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	155628000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	99418000
CY2022Q1	celu	Stock Issued During Period Value Reclassification Of Previously Exercised Stock Options StockIssuedDuringPeriodValueReclassificationOfPreviouslyExercisedStockOptions	441000
CY2022Q1	celu	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	46485000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-11000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2422000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-62867000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	89905000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-64017000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62867000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2363000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2284000
CY2023Q1	celu	Non Cash Lease Expense NonCashLeaseExpense	-19000
CY2022Q1	celu	Non Cash Lease Expense NonCashLeaseExpense	-1000
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	611000
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	235000
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1735000
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	20932000
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29633000
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3988000
CY2022Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2422000
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-18932000
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4849000
CY2023Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3000000
CY2023Q1	celu	Issuance Of Common Stock For Stem Cells To Be Used In Research And Development IssuanceOfCommonStockForStemCellsToBeUsedInResearchAndDevelopment	1000000
CY2023Q1	celu	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-110000
CY2022Q1	celu	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	1565000
CY2023Q1	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	1280000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-272000
CY2022Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-96000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-791000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1112000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1813000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5670000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1463000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	348000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2730000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1334000
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	729000
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	604000
CY2023Q1	celu	Accrued Research Development Software AccruedResearchDevelopmentSoftware	23675000
CY2022Q1	celu	Accrued Research Development Software AccruedResearchDevelopmentSoftware	1333000
CY2023Q1	celu	Increase Decrease In Right Of Use Assets And Lease Liabilities IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities	64000
CY2022Q1	celu	Increase Decrease In Right Of Use Assets And Lease Liabilities IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities	52000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	32000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	39000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14995000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34253000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	209000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1454000
CY2023Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3000000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3209000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1454000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1618000
CY2023Q1	celu	Proceeds From Issuance Of Senior Secured Bridge Loan And Warrants ProceedsFromIssuanceOfSeniorSecuredBridgeLoanAndWarrants	4994000
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9000000
CY2023Q1	celu	Proceeds From The Sale Of Common Stock In Atm Offering ProceedsFromTheSaleOfCommonStockInAtmOffering	136000
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46485000
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	53000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12759000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46495000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5445000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10788000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28802000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52076000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23357000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62864000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	251000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	697000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1015000
CY2023Q1	celu	Issuance Of Warrants On Senior Secured Bridge Loan IssuanceOfWarrantsOnSeniorSecuredBridgeLoan	274000
CY2023Q1	celu	Pipe Related Costs Included In Accrued Expenses PIPERelatedCostsIncludedInAccruedExpenses	-69000
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3510000
CY2022Q1	celu	Reclassification Of Option Liabilities To Equity ReclassificationOfOptionLiabilitiesToEquity	441000
CY2023Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-08-24
CY2023Q1	celu	Number Of Clinical Trials NumberOfClinicalTrials	2
CY2023Q1	celu	Area Of Building AreaOfBuilding	147215
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-63870000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14995000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-709513000
CY2023Q1	celu	Unrestricted Cash And Cash Equivalents UnrestrictedCashAndCashEquivalents	5700000
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2023Q1	celu	Instrument Specific Credit Risk Income InstrumentSpecificCreditRiskIncome	2810000
CY2023Q1	celu	Accumulated Other Comprehensive Income To Other Expense Upon Short Term Debt Conversion AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion	152000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2023Q1	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2023Q1	us-gaap	Change In Accounting Principle Accounting Standards Update Adoption Date ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate	2023-01-01
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	115310670
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	53921631
CY2023Q1	celu	Number Of Business Segments NumberOfBusinessSegments	3
CY2022Q1	celu	Number Of Business Segments NumberOfBusinessSegments	3
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Allowance for Credit Losses and Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">With the adoption of ASU 2016-13 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Financial Instruments — Credit Losses,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> as noted below, the Company recognizes credit losses based on a forward-looking current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, two of the Company's customers comprised </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company's outstanding gross accounts receivable. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, three of the Company's customers comprised </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">71</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company's outstanding gross accounts receivable. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company had two customers provide for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenue. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company had three customers provide for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current year presentation on the condensed consolidated balance sheets and condensed consolidated statements of cash flows between accrued expenses and accrued research and development ("R&D") software to separately present the Palantir cease-use liability recorded during the three months ended March 31, 2023 (See Note 9 for further information)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p>
CY2023Q1	us-gaap	Change In Accounting Principle Accounting Standards Update Immaterial Effect ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect	true
CY2023Q1	celu	Convertible Note Receivable ConvertibleNoteReceivable	2115000
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9669000
CY2023Q1	celu	Contingent Stock Consideration ContingentStockConsideration	76000
CY2023Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	30945000
CY2023Q1	celu	Warrant Liability Private Investment In Public Equity Warrants WarrantLiabilityPrivateInvestmentInPublicEquityWarrants	491000
CY2023Q1	celu	Warrant Liability Sponsor Warrants WarrantLiabilitySponsorWarrants	510000
CY2023Q1	celu	Warrant Liability Public Warrants WarrantLiabilityPublicWarrants	862000
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	119897000
CY2022Q4	celu	Convertible Note Receivable ConvertibleNoteReceivable	2514000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	14688000
CY2022Q4	celu	Contingent Stock Consideration ContingentStockConsideration	186000
CY2022Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	37603000
CY2022Q4	celu	Warrant Liability Private Investment In Public Equity Warrants WarrantLiabilityPrivateInvestmentInPublicEquityWarrants	1402000
CY2022Q4	celu	Warrant Liability Sponsor Warrants WarrantLiabilitySponsorWarrants	1190000
CY2022Q4	celu	Warrant Liability Public Warrants WarrantLiabilityPublicWarrants	1006000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	147332000
CY2022Q1	celu	Fair Value Assets Level One To Level Two Transfers Amount During Period FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod	0
CY2022Q1	celu	Fair Value Assets Level Two To Level One Transfers Amount During Period FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod	0
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2023Q1	celu	Fair Value Assets Level One To Level Two Transfers Amount During Period FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod	0
CY2023Q1	celu	Fair Value Assets Level Two To Level One Transfers Amount During Period FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2023Q1	celu	Percentage Of Stock Price Volatility Based On Historical Price Of Peer Companies PercentageOfStockPriceVolatilityBasedOnHistoricalPriceOfPeerCompanies	0.50
CY2023Q1	celu	Percentage Of Stock Price Volatility Based On Historical Price Of Company PercentageOfStockPriceVolatilityBasedOnHistoricalPriceOfCompany	0.50
CY2023Q1	celu	Warrant Liability WarrantLiability	1863000
CY2022Q4	celu	Warrant Liability WarrantLiability	3598000
CY2023Q1	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	984000
CY2022Q1	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	983000
CY2023Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	common stock are entitled to one vote per share
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	25962000
CY2022	celu	Private Investment In Public Equity Warrant Issuance PrivateInvestmentInPublicEquityWarrantIssuance	19745000
CY2022	celu	Gain Loss Recognized In Earnings From Change In Fair Values GainLossRecognizedInEarningsFromChangeInFairValues	42109000
CY2022Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	3598000
CY2022Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	3598000
CY2023Q1	celu	Gain Loss Recognized In Earnings From Change In Fair Values GainLossRecognizedInEarningsFromChangeInFairValues	1735000
CY2023Q1	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	1863000
CY2023Q1	celu	Fair Value Of Warrants FairValueOfWarrants	1863000
CY2022	celu	Fair Value Of Warrants FairValueOfWarrants	3598000
CY2023Q1	celu	Fair Value Of Convertible Note Receivable FairValueOfConvertibleNoteReceivable	2115000
CY2022Q4	celu	Fair Value Of Convertible Note Receivable FairValueOfConvertibleNoteReceivable	2514000
CY2023Q1	celu	Face Value Of Notes Receivable FaceValueOfNotesReceivable	4000000
CY2022Q4	celu	Face Value Of Notes Receivable FaceValueOfNotesReceivable	4000000
CY2023Q1	celu	Valuation Model That Relate To Sanuwave Common Stock ValuationModelThatRelateToSanuwaveCommonStock	0.04
CY2022Q4	celu	Valuation Model That Relate To Sanuwave Common Stock ValuationModelThatRelateToSanuwaveCommonStock	0.02
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P23Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1112
CY2023Q1	celu	Scheduleofyorkvilleshort Termdebtvaluationmodel Tabletextblock ScheduleofyorkvilleshortTermdebtvaluationmodelTabletextblock	<p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Significant inputs for the Yorkville short-term debt valuation model as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:83.051%;"/> <td style="width:2.016%;"/> <td style="width:1.0%;"/> <td style="width:12.933%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Common share price</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.29</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Credit spread</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13.71</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Dividend yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Term (years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.71</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.75</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Volatility</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">45.0</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Discount yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18.46</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2022Q4	celu	Valuation Input For Short Term Debt Share Price ValuationInputForShortTermDebtSharePrice	1.29
CY2022Q4	celu	Valuation Input For Short Term Debt Credit Spread ValuationInputForShortTermDebtCreditSpread	0.1371
CY2022Q4	celu	Valuation Input For Short Term Debt Dividend Yield ValuationInputForShortTermDebtDividendYield	0
CY2022	celu	Valuation Input For Short Term Debt Term ValuationInputForShortTermDebtTerm	P0Y8M15D
CY2022Q4	celu	Valuation Input For Short Term Debt Discount Yield ValuationInputForShortTermDebtDiscountYield	0.1846
CY2023Q1	celu	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	7784000
CY2022Q4	celu	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	7719000
CY2023Q1	celu	Inventory Work In Progress Current And Noncurrent InventoryWorkInProgressCurrentAndNoncurrent	14951000
CY2022Q4	celu	Inventory Work In Progress Current And Noncurrent InventoryWorkInProgressCurrentAndNoncurrent	12381000
CY2023Q1	celu	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	8473000
CY2022Q4	celu	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	9256000
CY2023Q1	celu	Inventory Gross Current And Noncurrent InventoryGrossCurrentAndNoncurrent	31208000
CY2022Q4	celu	Inventory Gross Current And Noncurrent InventoryGrossCurrentAndNoncurrent	29356000
CY2023Q1	celu	Inventory Reserve Current And Noncurrent InventoryReserveCurrentAndNoncurrent	1138000
CY2022Q4	celu	Inventory Reserve Current And Noncurrent InventoryReserveCurrentAndNoncurrent	1099000
CY2023Q1	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	30070000
CY2022Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	28257000
CY2023Q1	us-gaap	Inventory Net InventoryNet	5484000
CY2022Q4	us-gaap	Inventory Net InventoryNet	5308000
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	24586000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	22949000
CY2023Q1	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	30070000
CY2022Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	28257000
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	96209000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95986000
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22153000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20331000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74056000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75655000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1822000
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1743000
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29633000
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022Q4	us-gaap	Goodwill Goodwill	119694000
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29633000
CY2023Q1	us-gaap	Goodwill Goodwill	90061000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23993000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23993000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12040000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11499000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11953000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12494000
CY2023Q1	celu	Acquired Product Rights AcquiredProductRights	108500000
CY2022Q4	celu	Acquired Product Rights AcquiredProductRights	108500000
CY2022	celu	Indefinite Lived Intangible Assets Amortization Method IndefiniteLivedIntangibleAssetsAmortizationMethod	indefinite
CY2023Q1	celu	Indefinite Lived Intangible Assets Amortization Method IndefiniteLivedIntangibleAssetsAmortizationMethod	indefinite
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120453000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120994000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	541000
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	541000
CY2023Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2022Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	760000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	760000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	304000
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	325000
CY2023Q1	us-gaap	Lease Cost LeaseCost	1064000
CY2022Q1	us-gaap	Lease Cost LeaseCost	1085000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	46000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	715000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	708000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2181000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2969000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3042000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3116000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3190000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	70341000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	84839000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	56790000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28049000
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	43590201
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.765
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.39
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	482000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3988000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2422000
CY2022Q1	celu	Indirect Expenses IndirectExpenses	6955000
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-41614000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3935000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5935000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4492000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4067000
CY2023Q1	celu	Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue	1195000
CY2022Q1	celu	Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue	1649000
CY2023Q1	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	1163000
CY2022Q1	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	1610000
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4524000
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4106000
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2023Q1	us-gaap	Assets Assets	362416000
CY2022Q4	us-gaap	Assets Assets	401066000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3935000
CY2023Q1	us-gaap	Gross Profit GrossProfit	1932000
CY2023Q1	us-gaap	Direct Operating Costs DirectOperatingCosts	54670000
CY2023Q1	celu	Segment Contribution SegmentContribution	-52738000
CY2023Q1	celu	Indirect Expenses IndirectExpenses	-11132000
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-63870000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5935000
CY2022Q1	us-gaap	Gross Profit GrossProfit	1909000
CY2022Q1	us-gaap	Direct Operating Costs DirectOperatingCosts	36568000
CY2022Q1	celu	Segment Contribution SegmentContribution	-34659000

Files In Submission

Name	View Source	Status
0000950170-23-023462-index-headers.html	Edgar Link	pending
0000950170-23-023462-index.html	Edgar Link	pending
0000950170-23-023462.txt	Edgar Link	pending
0000950170-23-023462-xbrl.zip	Edgar Link	pending
celu-20230331.htm	Edgar Link	pending
celu-20230331.xsd	Edgar Link	pending
celu-ex31_1.htm	Edgar Link	pending
celu-ex31_2.htm	Edgar Link	pending
celu-20230331_cal.xml	Edgar Link	unprocessable
celu-20230331_def.xml	Edgar Link	unprocessable
celu-20230331_pre.xml	Edgar Link	unprocessable
celu-20230331_lab.xml	Edgar Link	unprocessable
celu-20230331_htm.xml	Edgar Link	completed
celu-ex32_1.htm	Edgar Link	pending
celu-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELU
Celularity Inc Stock $celu

2023 Q2 Form 10-Q Financial Statement

#000095017023023462 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELU Celularity Inc Stock $celu

2023 Q2 Form 10-Q Financial Statement

#000095017023023462 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELU
Celularity Inc Stock $celu